Drug Trial Radar · NCT07914088
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 21, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Arjil Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is composed of a two-arm, double-blind, randomized, placebo-controlled, Phase II study to evaluate the efficacy of AR100DP1 compared to placebo on AD lesion area(s) in subjects with mild to moderate AD.
Conditions
- Dermatitis Atopic
Interventions
0.5% AR100DP1Drug
Investigational drug administered according to the protocol schedule.
PlaceboOther
Visually identical placebo containing no active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change of IGA to 0 or 1 at visit 4 after 14 days treatmentTime frame: From Visit 2 (Day 1) to Visit 4 (Day 15) (14 days treatment)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Taipei Medical University Hospital
Taipei, Taiwan, Taiwan · Recruiting
Chang Gung Memorial Hospital-Linkou
Taoyuan, Taiwan, Taiwan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.